JS111 capsules (AP-L1898)

Preclinical

SSuzhou Junjing BioSciences Co., Ltd.

JS111 capsules (AP-L1898) is one of 83 therapeutic programs targeting NSCLC. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

NSCLCActive, not recruiting

Non-Small Cell Lung CarcinomaNot yet recruiting

NSCLCPreclinical

Active, not recruiting

Non-Small Cell Lung CarcinomaPreclinical

Not yet recruiting

Competition

Competitive Landscape

55 competitors in NSCLC

#DrugCompanyPhaseTrials

Iressa

AstraZeneca

Approved

3 2

Taxotere

AAvyxa

Phase 3

5 3

Alimta

SShawn Eagle

Phase 3

4 4

Navmi

SSummit Therapeutics

Phase 3

1 5

Taxol

Teva

Phase 2

3 6

Tecentriq

Roche

Phase 2

3 7

Alecensa

Roche

Phase 2

2 8

Libtayo

Regeneron

Phase 2

1 9

Firmonertinib

AAllist Pharmaceuticals, Inc.

Phase 3

2 10

SYS6010

CCSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

PreclinicalActive, not recruiting

NSCLC

NCT06940401

Q3 2029

PreclinicalNot yet recruiting

Non-Small Cell Lung Carcinoma

NCT07714304

Clinical

Trials by Indication[1]

Non-Small Cell Lung Carcinoma1 trial

A Phase II, Open-Label, Single-Arm Study of JS212 in Combination With JS111 as First-Line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)

Not yet recruiting·HHuan Zhou·Preclinical·NCT07714304·20 enrolled

NSCLC1 trial

A Phase I/II Clinical Study to Evaluate JS111 Capsules in Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations.

Active, not recruiting·SSuzhou Junjing BioSciences Co., Ltd.·Preclinical·NCT06940401·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for JS111 capsules (AP-L1898). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for JS111 capsules (AP-L1898). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Suzhou Junjing BioSciences Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: SSuzhou Junjing BioSciences Co., Ltd.

JS111 capsules (AP-L1898)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q3 2029

Trials by Indication[1]

Non-Small Cell Lung Carcinoma1 trial

NSCLC1 trial

References

Drug Info

Quick Facts

Related News